India, July 27 -- The following biotech stocks reached 52-week highs on July 24, 2026, driven by key catalysts like the upcoming release of quarterly reports or various regulatory milestones.
Inhibikase Therapeutics Inc. (IKT)
Inhikibase Therapeutics is a clinical-stage pharmaceutical company specializing in developing therapies for cardiopulmonary diseases, primarily pulmonary arterial hypertension (PAH). Shares increased to $2.53, a 52-week high during intraday trading on Friday.
The lead drug candidate of the company, IKT-001, is an oral formulation of imatinib mesylate developed for the treatment of PAH that received an Orphan Drug designation from the U.S. Food and Drug Administration (FDA) on Thursday. The drug is currently being e...